Stanford scientists turn a cancer driver into a kill switch
How does rewiring a cancer protein differ from blocking it?
Researchers at Stanford Medicine have engineered a molecule that converts a cancer-promoting protein into a tumor-killing agent. In laboratory mice with aggressive lymphoma, the treatment eliminated tumors within 11 days. The approach reprograms a key driver of cancer growth to instead trigger cell death, offering a promising new strategy for treating hard-to-target malignancies.
The molecule, designed by Stanford scientists, targets BCL6, a protein known to drive the development and survival of diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma. Rather than simply inhibiting BCL6, the new compound binds to it and changes its function, turning it from a cancer promoter into an activator of genes that cause cancer cells to self-destruct. This method, called protein rewiring, avoids the resistance often seen with traditional inhibitors. In mouse models, the treatment led to complete tumor regression with no observable side effects over the observation period.
Can this strategy work for other cancers driven by similar proteins?
Unlike conventional drugs that block a protein’s activity, this approach alters the protein’s behavior so it actively fights the cancer. By changing BCL6’s role from supporting tumor growth to triggering cell death, the therapy exploits the cancer’s own machinery against it. This could reduce the likelihood of resistance, as the cancer cells cannot easily mutate to escape a mechanism that turns their strength into a weakness. Early data suggest the effect is rapid and durable in preclinical models.
Scientists are exploring whether the same rewiring principle can be applied to other oncoproteins that contribute to cancer progression. BCL6 is part of a larger family of transcription factors implicated in various cancers, and the modular design of the molecule allows for potential adaptation to other targets. While the current findings are limited to lymphoma models, the platform could inspire new therapies for breast, lung, and prostate cancers where similar drivers play a role. Researchers caution that human trials are still years away but emphasize the significance of proving the concept in vivo.
What is BCL6 and why is it important in lymphoma? BCL6 is a protein that regulates gene expression and helps B cells survive and proliferate. In diffuse large B-cell lymphoma, it is often overactive and blocks signals that would normally tell cancer cells to die, making it a central driver of the disease.
Frequently Asked Questions
How long did it take for tumors to disappear in mice? In the study, tumors were completely eliminated within 11 days of treatment onset, with no signs of regrowth during the monitored period.
Is this treatment ready for human use? No. The results are from preclinical studies in mice. Further testing is needed to assess safety, effectiveness, and optimal dosing in humans before clinical trials can begin.